Sglt2 Inhibitors Versus Metformin

Sodium Glucose Transporter 2 Inhibitors Versus Metformin on ...

Among patients with diabetes with low cardiovascular risk, initial use of SGLT2 (sodium‐glucose cotransporter 2) inhibitors confers a similar risk for all‐cause mortality and cardiovascular and renal events as those initially on metformin .

Pharmacokinetics of metformin versus SGLT2 inhibitors As shown in Table 1, metformin and SGLT2 inhibitors have very little overlap in pharmacokinetic parameters, indicating that significant drug-drug interactions are unlikely when given together as a fixed-dose combination (FDC).

Comparative effectiveness of SGLT2i vs. Metformin

This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease (Kannel & McGee, 1979; Savage, 1996).

Furthermore, visual representations like the one above help us fully grasp the concept of Sglt2 Inhibitors Versus Metformin.

Background: Contemporary evidence supports the cardiovascular and renal benefits of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in patients with diabetes. While metformin has traditionally been recommended as a first-line treatment, its exact role in improving cardiovascular outcomes remains uncertain. This study aims to evaluate the impact of combination therapy with metformin on the ...

Metformin versus SGLT

In conclusion, while the combination of metformin and SGLT2 inhibitors would be a better option in improving glycemic control with a low risk of hypoglycemia, an increase in the risk of metabolic acidosis during combination therapy may be borne in mind.